Contrasting Immuneering (NASDAQ:IMRX) & Clearmind Medicine (NASDAQ:CMND)

Immuneering (NASDAQ:IMRX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Insider & Institutional Ownership

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 25.0% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Immuneering and Clearmind Medicine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	$320,000.00	297.46	-$53.47 million	($1.87)	-1.72
Clearmind Medicine	N/A	N/A	-$8.62 million	N/A	N/A

Clearmind Medicine has lower revenue, but higher earnings than Immuneering.

Profitability

This table compares Immuneering and Clearmind Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-66.03%	-58.78%
Clearmind Medicine	N/A	-205.13%	-94.22%

Analyst Ratings

This is a breakdown of recent recommendations for Immuneering and Clearmind Medicine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	0	3	4	0	2.57
Clearmind Medicine	0	0	0	0	N/A

Immuneering presently has a consensus price target of $12.60, indicating a potential upside of 292.52%. Given Immuneering’s higher possible upside, equities research analysts plainly believe Immuneering is more favorable than Clearmind Medicine.

Volatility & Risk

Immuneering has a beta of -0.61, suggesting that its stock price is 161% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Summary

Immuneering beats Clearmind Medicine on 6 of the 9 factors compared between the two stocks.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.